Abstract 5419
Background
Multiple mechanisms can directly influence body compositions (bcomp) in cancer: tumor-dependent chronic inflammation, leading to (a) anorexia and multiple neuroendocrine changes, (b) patient-dependent treatment related effects, and (c) in esophageal cancer, mechanical alterations with weight loss. Supportive management depends on understanding the cancer frailty determinants that lead to poor outcomes.
Methods
We retrospectively identified MEC patients (pts) treated in Toronto, Canada (2007-2014). Bcomp was assessed at presentation, using computed tomography, and included skeletal muscle index (SMI), visceral (VA) and subcutaneous adiposity (SA). Two outcome-blinded radiologists (Intraclass correlation, 0.92-1.00) assessed the L3 level, using SliceOMatic software. Published sex and BMI-dependent Bcomp cut-offs were used to define cancer associated sarcopenia. Cox proportional hazard models generated adjusted hazard ratios (aHR) and Kaplan-Meier curves estimated survival.
Results
Of 127 pts, 83% were male; 94% Caucasian; median age at diagnosis 61y (29-88); 80% were stage IV de novo. Mean body mass index (BMI) was 24.7; 69%/27%/3% were adeno/squamous cell /large cell carcinoma. Median overall (OS) and progression free survival (PFS) were: 6.4 (OS) and 1.5 mos (PFS). Median follow-up time was 5.6 mos. 49% were sarcopenic at baseline; of 44 pts with BMI > =25, 41% were sarcopenic. Univariable analyses identified albumin, LDH, and arcopenia as being inversely associated with OS and PFS. Multivariable models showed that sarcopenia was independently associated with worse OS (aHR=1.74, 95%CI 1.06-2.86, p = 0.03), and worse PFS (aHR=1.95, 95%CI 1.10-3.44, p = 0.02). In 76 pts receiving chemotherapy at diagnosis, less total adiposity (VA+SA) showed a trend towards worse OS (aHR=0.99 95%CI 0.99-1.00 p = 0.07 as continuous variable).
Conclusions
Sarcopenia at baseline is inversely related with OS and PFS in MEC. Our MEC patients had a higher incidence of sarcopenic obesity compared to cancer populations in the literature (9%). Future studies are needed to better characterize muscle and adiposity underlying biological importance in MEC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4413 - Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Presenter: Ghassan Abou-Alfa
Session: Poster Display session 2
Resources:
Abstract
4710 - Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Lorenza Rimassa
Session: Poster Display session 2
Resources:
Abstract
5509 - A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment (NCT03126435)
Presenter: Li-Tzong Chen
Session: Poster Display session 2
Resources:
Abstract
1463 - Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
Presenter: Sylvie Lorenzen
Session: Poster Display session 2
Resources:
Abstract
2392 - GLOW: Randomized Phase 3 Study of Zolbetuximab + CAPOX Compared With Placebo + CAPOX as First-line Treatment of Patients With CLD18.2⁺/HER2⁻ Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Presenter: Manish Shah
Session: Poster Display session 2
Resources:
Abstract
5217 - PRODIGE67_UCGI33 ARION: Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial
Presenter: Rosine Guimbaud
Session: Poster Display session 2
Resources:
Abstract
1726 - Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT
Presenter: Kenro Hirata
Session: Poster Display session 2
Resources:
Abstract
2279 - FRONTiER: A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
Presenter: Shun Yamamoto
Session: Poster Display session 2
Resources:
Abstract
4912 - A phase Ib/II study of AK104, a PD-1/CTLA-4 Bispecific Antibody, Combined With mXELOX as First-line Therapy for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Presenter: Jiafu Ji
Session: Poster Display session 2
Resources:
Abstract
3780 - Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
Presenter: Salah-Eddin Al-Batran
Session: Poster Display session 2
Resources:
Abstract